Emm, a UK-based femtech company developing what it calls the world’s first smart menstrual health solution, has raised over $9 million (£6.8 million) in an oversubscribed funding round. The investment represents a significant milestone for the company as it prepares for a 2026 consumer launch.
The round was led by Lunar Ventures, with participation from The Labcorp Venture Fund, Tiny VC, BlueLion Global, and Alumni Ventures — known for backing consumer health brands such as Oura and Levels. Additional support came from several notable angel investors including Amar Shah of Wayve, Vivek Garipalli of Clover Health and Wormhole Capital, and former Oura CEO Harpreet Rai.
Emm plans to use the funding to bring its product to market and continue developing technology that provides users with deeper insight into their menstrual cycles and overall reproductive health.
Founded by CEO Jenny Button, Emm aims to address a longstanding gap in women’s health technology. Button, drawing from her own experience, set out to build tools that offer the same level of tracking, measurement, and insight long available for sleep, fitness, and metabolic health — but largely absent in menstrual care. Emm’s team of engineers, designers, clinical experts, and researchers has focused on creating a data-driven, user-controlled system for monitoring menstrual health.
The company is developing a new category in biowearables called smart menstrual care. Its system includes a medical-grade silicone menstrual cup embedded with advanced, ultra-thin sensors; a connected mobile app that tracks menstrual flow, duration and patterns; and a privacy-first data model that keeps users in control of their personal health information.
Emm’s leadership argues that innovation in this space is long overdue. Despite impacting half the global population, menstrual health remains underfunded and under-researched across both medical and technology sectors. The company positions its product as both a commercial breakthrough and a step toward raising the overall standard of women’s health innovation.
A UK launch is planned for early 2026, with international expansion expected afterward. Emm is inviting consumers to join its waitlist to receive updates as the rollout approaches.
The company emphasizes that menstrual health data should be accessible, actionable, and treated with the same seriousness as other key health metrics. It frames its mission around giving people greater autonomy over understanding their cycles and advocating for their own health.
